FTHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Faeth Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$19.44+0.64 (+3.40%)
Close on Oct 19, 2026
- Market cap
- $109.70M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
54.5%
14M of 26M shares
Institutional holders
45
22 new, 7 sold out
Net institutional buying
12M
In Q2 2026
Insider trades, 12 months
49 buys · 45 sales
Net bought $250.44K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| VK Services, LLC | 2,632,232 | 10.20% | 13G (passive) | Jun 15, 2026 |
| S2G Investments, LLC | 2,575,401 | 9.99% | 13G (passive) | Jun 15, 2026 |
| Aaron Cowen | 2,020,103 | 7.80% | 13G (passive) | Jun 15, 2026 |
| Millennium Group Management LLC | 128,761 | 9.60% | 13G (passive) | Feb 24, 2026 |
| Ortav Yehudai | 126,010 | 9.90% | 13G (passive) | Feb 18, 2026 |
| David Johnson | 126,002 | 9.40% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of FTH | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Suvretta Capital Management, LLC | 2,020,103 | 7.82% | $50.50M | +1,985,554 | 0.92% |
| Avoro Capital Advisors LLC | 1,444,039 | 5.59% | $36.10M | New | 0.32% |
| Baker Bros. Advisors LP | 1,286,411 | 4.98% | $32.16M | New | 0.16% |
| Balyasny Asset Management L.P. | 1,042,198 | 4.03% | $26.05M | +1,025,993 | 0.03% |
| Cormorant Asset Management, LP | 1,028,242 | 3.98% | $7.66M | +722,020 | 0.39% |
| Vivo Capital, LLC | 722,020 | 2.79% | $18.05M | – | 1.65% |
| Ra Capital Management, L.P. | 722,020 | 2.79% | $18.05M | New | 0.16% |
| Logos Global Management LP | 722,020 | 2.79% | $18.05M | +692,020 | 0.78% |
| Fairmount Funds Management LLC | 722,020 | 2.79% | $18.05M | New | 1.19% |
| Caligan Partners LP | 629,467 | 2.44% | $15.74M | +503,465 | 0.74% |
| B Group, Inc. | 610,169 | 2.36% | $15.25M | New | 7.16% |
| Trails Edge Capital Partners, LP | 515,335 | 1.99% | $12.88M | +390,335 | 2.05% |
| Franklin Resources Inc | 494,516 | 1.91% | $12.36M | +361,010 | 0.00% |
| ADAR1 Capital Management, LLC | 361,010 | 1.40% | $9.03M | New | 0.41% |
| Octagon Capital Advisors LP | 361,010 | 1.40% | $9.03M | New | 0.81% |
| Marshall Wace, Llp | 206,508 | 0.80% | $5.16M | +140,778 | 0.00% |
| Boxer Capital Management, LLC | 180,505 | 0.70% | $4.51M | New | 0.34% |
| Patient Square Capital LP | 175,050 | 0.68% | $4.38M | New | 0.68% |
| Alyeska Investment Group, L.P. | 144,404 | 0.56% | $3.61M | New | 0.01% |
| Affinity Asset Advisors, LLC | 144,404 | 0.56% | $3.61M | New | 0.16% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 45 | 14M | 54.5% | 22 / 17 | 2 / 7 | 12M | 1M |
| Q1 2026 | 30 | 2M | 8.9% | 22 / 3 | 1 / 2 | 2M | 0M |
| Q4 2025 | 10 | 0M | 0.2% | 2 / 1 | 4 / 1 | 0M | 0M |
| Q3 2025 | 9 | 0M | 0.2% | 1 / 2 | 1 / 2 | 0M | 0M |
| Q2 2025 | 10 | 0M | 0.3% | 10 / 0 | 0 / 1 | 0M | 0M |
| Q1 2025 | 1 | 0M | 0.0% | 1 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of FTH | Value | % of fund | As of |
|---|---|---|---|---|---|
| Franklin Biotechnology Discovery Fund | 180,711 | 0.70% | $4.92M | 0.43% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 10,115 | 0.04% | $252.88K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 4,576 | 0.02% | $96.74K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 3,192 | 0.01% | $79.80K | 0.01% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 1,416 | 0.01% | $29.93K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 1,253 | 0.00% | $26.49K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 578 | 0.00% | $12.22K | 0.00% | May 31, 2026 |
| 1290 VT Micro Cap Portfolio | 210 | 0.00% | $5.25K | 0.00% | Jun 30, 2026 |
| Total Stock Market Index Trust | 41 | 0.00% | $1.03K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Anand Kiran Parikh | President and CEO, Director | 764,234 | 2.96% | Jul 23, 2026 |
| John Celebi | PRESIDENT AND CEO, Director | 105,862 | 0.41% | Feb 26, 2025 |
| Josiah Craver | PAO | – | – | Jul 23, 2026 |
| Brian C. Stephenson | Chief Financial Officer | 46,088 | 0.18% | Jul 1, 2026 |
| Christopher Gerry | President & PEO | 1,574 | 0.01% | Jun 12, 2026 |
| der Horst Edward van | CHIEF SCIENTIFIC OFFICER | 59,794 | 0.23% | Feb 26, 2025 |
| Stephanie Krebs | Chief Business Officer | – | – | Feb 14, 2025 |
| Karen H. Vousden | Director | 42,631 | 0.16% | Sep 15, 2026 |
| Saira Ramasastry | Director | – | – | Jun 16, 2026 |
| Stephen M. Hahn | Director | 44,763 | 0.17% | Jun 16, 2026 |
| Phillip B. Donenberg | Director | – | – | Jun 12, 2026 |
| Bob Holmen | Director | 25,598 | 0.10% | Jun 12, 2026 |
| Thomas G. Ricks | Director | 343,863 | 1.33% | May 23, 2025 |
| William R. Ringo | Director | 23,399 | 0.09% | May 23, 2025 |
| Kristian Humer | Director | 8,932 | 0.03% | May 23, 2025 |
| Vinod Khosla | 10% owner | 1,643,349 | 6.36% | Jul 28, 2026 |
| VK Services, LLC | 10% owner | – | – | Jul 28, 2026 |
| Khosla Ventures VI, L.P. | 10% owner | – | – | Jul 28, 2026 |
| Khosla Ventures Associates VI, LLC | 10% owner | – | – | Jul 28, 2026 |
| Khosla Ventures Seed D, L.P. | 10% owner | – | – | Jul 28, 2026 |
| Khosla Ventures Seed Associates D, LLC | 10% owner | – | – | Jul 28, 2026 |
| BioPharma Inc Cambrian | 10% owner | 130,142 | 0.50% | Jun 1, 2026 |
| James Peyer | 10% owner | 286,125 | 1.11% | Jun 1, 2026 |
| Group Management Llc Millennium | 10% owner | – | – | May 15, 2026 |
| Israel A. Englander | 10% owner | – | – | May 15, 2026 |
| Management Llc Millennium | 10% owner | 147,731 | 0.57% | May 15, 2026 |
| Opportunities Ii Llc Ics | 10% owner | 127,095 | 0.49% | May 15, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Brian C. Stephenson Chief Financial Officer | Jul 1, 2026 | Buy | +4,400 | $23.40 | $102.96K | 46,088 |
| Brian C. Stephenson Chief Financial Officer | Jul 1, 2026 | Buy | +600 | $24.22 | $14.53K | 46,688 |
| Brian C. Stephenson Chief Financial Officer | Jun 30, 2026 | Buy | +4,255 | $24.98 | $106.29K | 41,688 |
| Brian C. Stephenson Chief Financial Officer | Jun 30, 2026 | Buy | +1,910 | $22.95 | $43.83K | 35,795 |
| Brian C. Stephenson Chief Financial Officer | Jun 30, 2026 | Buy | +1,638 | $23.88 | $39.12K | 37,433 |
| Brian C. Stephenson Chief Financial Officer | Jun 29, 2026 | Buy | +831 | $23.34 | $19.40K | 33,885 |
| Brian C. Stephenson Chief Financial Officer | Jun 26, 2026 | Buy | +580 | $23.61 | $13.69K | 27,384 |
| Brian C. Stephenson Chief Financial Officer | Jun 26, 2026 | Buy | +4,212 | $24.90 | $104.88K | 31,596 |
| Brian C. Stephenson Chief Financial Officer | Jun 26, 2026 | Buy | +1,358 | $25.55 | $34.70K | 32,954 |
| Brian C. Stephenson Chief Financial Officer | Jun 26, 2026 | Buy | +100 | $26.39 | $2.64K | 33,054 |
| Brian C. Stephenson Chief Financial Officer | Jun 24, 2026 | Buy | +2,891 | $25.22 | $72.91K | 20,304 |
| Brian C. Stephenson Chief Financial Officer | Jun 24, 2026 | Buy | +3,000 | $25.98 | $77.94K | 23,304 |
| Brian C. Stephenson Chief Financial Officer | Jun 24, 2026 | Buy | +3,400 | $26.98 | $91.73K | 26,704 |
| Brian C. Stephenson Chief Financial Officer | Jun 24, 2026 | Buy | +100 | $27.77 | $2.78K | 26,804 |
| Brian C. Stephenson Chief Financial Officer | Jun 23, 2026 | Buy | +425 | $25.91 | $11.01K | 17,413 |
| Brian C. Stephenson Chief Financial Officer | Jun 23, 2026 | Buy | +1,969 | $24.84 | $48.91K | 16,988 |
| Brian C. Stephenson Chief Financial Officer | Jun 23, 2026 | Buy | +6,836 | $24.12 | $164.88K | 15,019 |
| Brian C. Stephenson Chief Financial Officer | Jun 22, 2026 | Buy | +1,797 | $20.23 | $36.35K | 1,797 |
| Brian C. Stephenson Chief Financial Officer | Jun 22, 2026 | Buy | +356 | $23.95 | $8.53K | 8,183 |
| Brian C. Stephenson Chief Financial Officer | Jun 22, 2026 | Buy | +3,329 | $23.28 | $77.50K | 7,827 |
| Brian C. Stephenson Chief Financial Officer | Jun 22, 2026 | Buy | +1,583 | $22.40 | $35.46K | 4,498 |
| Brian C. Stephenson Chief Financial Officer | Jun 22, 2026 | Buy | +1,118 | $20.82 | $23.28K | 2,915 |
| Anand Kiran Parikh President and CEO, Director | Jun 22, 2026 | Buy | +2,806 | $19.76 | $55.45K | 764,234 |
| Anand Kiran Parikh President and CEO, Director | Jun 22, 2026 | Option exercise | +8,213 | $1.16 | $9.53K | 817,699 |
| Anand Kiran Parikh President and CEO, Director | Jun 22, 2026 | Option exercise | +45,252 | $1.16 | $52.49K | 809,486 |
| Stephen M. Hahn Director | Jun 15, 2026 | Conversion | +44,763 | – | – | 44,763 |
| Anand Kiran Parikh President and CEO, Director | Jun 15, 2026 | Conversion | +761,428 | – | – | 761,428 |
| James Peyer 10% owner | Jun 1, 2026 | Sale | −476 | $21.14 | $10.06K | 130,142 |
| James Peyer 10% owner | Jun 1, 2026 | Sale | −24,524 | $20.00 | $490.48K | 130,618 |
| BioPharma Inc Cambrian 10% owner | Jun 1, 2026 | Sale | −476 | $21.14 | $10.06K | 130,142 |
| BioPharma Inc Cambrian 10% owner | Jun 1, 2026 | Sale | −24,524 | $20.00 | $490.48K | 130,618 |
| Opportunities Ii Llc Ics 10% owner | Apr 7, 2026 | Sale | −1,108 | $33.38 | $36.99K | 133,986 |
| Opportunities Ii Llc Ics 10% owner | Apr 7, 2026 | Sale | −300 | $32.25 | $9.68K | 133,986 |
| Opportunities Ii Llc Ics 10% owner | Apr 7, 2026 | Sale | −4,423 | $31.38 | $138.79K | 133,986 |
| Opportunities Ii Llc Ics 10% owner | Apr 7, 2026 | Sale | −205 | $29.71 | $6.09K | 133,986 |
| Opportunities Ii Llc Ics 10% owner | Apr 7, 2026 | Sale | −2,115 | $28.94 | $61.21K | 133,986 |
| Opportunities Ii Llc Ics 10% owner | Apr 7, 2026 | Buy | +1,108 | $33.38 | $36.99K | 133,986 |
| Opportunities Ii Llc Ics 10% owner | Apr 6, 2026 | Buy | +1,104 | $31.02 | $34.25K | 141,029 |
| Opportunities Ii Llc Ics 10% owner | Apr 6, 2026 | Sale | −1,214 | $31.02 | $37.66K | 141,029 |
| Opportunities Ii Llc Ics 10% owner | Apr 6, 2026 | Sale | −45 | $31.96 | $1.44K | 141,029 |
| Opportunities Ii Llc Ics 10% owner | Apr 2, 2026 | Buy | +701 | $35.55 | $24.92K | 144,974 |
| Opportunities Ii Llc Ics 10% owner | Apr 2, 2026 | Buy | +26 | $33.47 | $870 | 144,974 |
| Opportunities Ii Llc Ics 10% owner | Apr 2, 2026 | Buy | +1,276 | $34.75 | $44.34K | 144,974 |
| Opportunities Ii Llc Ics 10% owner | Apr 2, 2026 | Sale | −3,099 | $30.86 | $95.64K | 144,974 |
| Opportunities Ii Llc Ics 10% owner | Apr 2, 2026 | Sale | −1,265 | $31.75 | $40.16K | 144,974 |
| Opportunities Ii Llc Ics 10% owner | Apr 2, 2026 | Sale | −1,794 | $32.60 | $58.48K | 144,974 |
| Opportunities Ii Llc Ics 10% owner | Apr 2, 2026 | Sale | −374 | $33.35 | $12.47K | 144,974 |
| Opportunities Ii Llc Ics 10% owner | Apr 2, 2026 | Sale | −1,134 | $34.80 | $39.46K | 144,974 |
| Management Llc Millennium 10% owner | Apr 1, 2026 | Buy | +3,401 | $35.46 | $120.60K | 147,731 |
| Management Llc Millennium 10% owner | Apr 1, 2026 | Sale | −1,104 | $31.52 | $34.80K | 147,731 |
| Management Llc Millennium 10% owner | Apr 1, 2026 | Sale | −46 | $34.75 | $1.60K | 147,731 |
| Management Llc Millennium 10% owner | Apr 1, 2026 | Buy | +1,161 | $31.53 | $36.61K | 147,731 |
| Management Llc Millennium 10% owner | Apr 1, 2026 | Buy | +1,613 | $34.59 | $55.79K | 147,731 |
| Management Llc Millennium 10% owner | Mar 31, 2026 | Sale | −87 | $31.52 | $2.74K | 146,657 |
| Management Llc Millennium 10% owner | Mar 31, 2026 | Sale | −5 | $28.41 | $142 | 146,657 |
| Management Llc Millennium 10% owner | Mar 31, 2026 | Sale | −57 | $27.11 | $1.55K | 146,657 |
| Management Llc Millennium 10% owner | Mar 31, 2026 | Sale | −1,251 | $25.17 | $31.49K | 146,657 |
| Management Llc Millennium 10% owner | Mar 31, 2026 | Sale | −191 | $24.28 | $4.64K | 146,657 |
| Management Llc Millennium 10% owner | Mar 31, 2026 | Buy | +411 | $32.60 | $13.40K | 146,657 |
| Management Llc Millennium 10% owner | Mar 31, 2026 | Buy | +1,957 | $31.45 | $61.55K | 146,657 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| BioPharma Inc Cambrian 10% Stockholder | Aug 11, 2026 | 130,142 | $3.64M | Jul 22, 2026 | Private Placement |
| BioPharma Inc Cambrian 10% Stockholder | Apr 29, 2026 | 155,142 | $4.96M | Apr 29, 2026 | Private Placement |
| John Celebi Former Officer | Feb 24, 2026 | 3,374 | $116.36K | Feb 24, 2026 | Option Granted 02/15/2023 |
| James Peyer Fomer Director | Feb 18, 2026 | 950 | $25.77K | Feb 18, 2026 | Option Granted 06/11/2024 |
| William R. Ringo Former Director | Jan 27, 2026 | 1,169 | $11.49K | Jan 27, 2026 | Restricted Stock Vesting |
| James Peyer Former Director | Dec 9, 2025 | 841 | $6.71K | Dec 9, 2025 | Restricted Stock Vesting |
| BioPharma Inc Cambrian 10% Stockholder | Dec 4, 2025 | 5,844 | $50.90K | Dec 4, 2025 | Open Market Purchase |
| BioPharma Inc Cambrian 10% Stockholder | Dec 4, 2025 | 21,222 | $184.84K | Dec 4, 2025 | Open Market Purchase |